Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient

Anne Katrin Berger1†, Georg Martin Haag1†, Martin Ehmann2, Anne Byl3, Dirk Jäger1 and Christoph Springfeld1

Abstract

Background: Pancreatic cancer occurs more frequently in older patients, but these are underrepresented in the phase III clinical studies that established the current treatment standards. This leads to uncertainty regarding the treatment of older patients with potentially toxic but active regimens like FOLFIRINOX.

Methods: We conducted a retrospective analysis of patients treated according to the FOLFIRINOX protocol at our institution between 2010 and 2014 with a focus on older patients.

Results: Overall survival in our cohort was 10.2 months. Only 43% of patients did not need dose adaptations, but dose reductions did not lead to an inferior survival. We did not find evidence that patients aged 65 years and older deemed fit enough for palliative treatment had more toxicities or a worse outcome than younger patients.

Conclusion: We conclude that treatment with the FOLFIRINOX protocol in patients with pancreatic cancer should not be withheld from patients solely based on their chronological age but rather be based on the patient’s performance status and comorbidities.

Keywords: Pancreatic cancer, Elderly patients, Folfirinox, Toxicity

Background

Cancer occurs more frequently in elderly people, and the current demographic changes with an aging population in Western countries will therefore result in a rising incidence of cancer and an increasing amount of older cancer patients [1–3]. For the US, it has been estimated that by 2030, approximately 70% of all cancers will be diagnosed in adults older than 65 years [4]. In contrast to this development, older patients remain underrepresented in the clinical cancer studies that establish standard treatment regimens [5]. There is widespread critique concerning this issue, but to date, trial results have to be extrapolated to the older population, although this approach remains questionable [6]. Fear of increased toxicities and uncertainty concerning both clinical treatment benefit and the patient’s physical resources may cause limitation of tumor-specific therapies in older patients. Ensuring an adequate antitumor treatment while avoiding toxicity is a challenging task for geriatric oncology in daily routine.

For pancreatic adenocarcinoma, the fourth common cause of cancer-related death in the US [7], approximately two-thirds of cases are diagnosed in patients over 65 years [8]. The overall 5-year survival rate is about 6% and remains the poorest of all major malignancies [9, 10]. Because the majority of tumors is irresectable or recurs after surgery, systemic palliative treatment is needed for almost every patient [11]. Despite its limited activity, single-agent gemcitabine was the standard palliative first-
line treatment for patients with advanced disease for more than a decade [12], until therapy options improved in 2011. In the landmark PRODIGE 4 trial, the FOLFIRINOX protocol had an impressive response rate of 31.6%, and it significantly improved median overall survival (OS) from 6.8 months in the gemcitabine monotherapy arm to 11.1 months [13]. More recently, this protocol has also been used successfully in patients with irresectable, locally advanced disease to achieve resectability and therefore offering a chance for cure [14]. The impressive results of the FOLFIRINOX protocol are accompanied by significantly increased grade 3 and 4 toxicities, mainly myelosuppression, diarrhea and peripheral neuropathy. Concerns regarding safety in the palliative setting have been raised immediately [15]. Likewise, the study population was criticized as heavily selected (young age, excellent performance status, mostly “non-head” tumors), not representing the average “real-life” patient. Subsequent retrospective clinical analyses confirmed the substantial toxicity profile, and modifications of the regimen are commonly recommended [16–18]. In 2013, therapeutic options further increased with publication of the MPACT trial. In this study, the addition of nab-paclitaxel to gemcitabine therapy increased the median overall survival from 6.6 to 8.7 months [19].

Thus, oncologists might be reluctant to apply FOLFIRINOX to older patients. Given the undoubted advantages in response rate and survival, older cancer patients might be at risk for therapeutic disparity and undertreatment. We conducted a retrospective analysis of patients with advanced pancreatic cancer under palliative first-line treatment with FOLFIRINOX at the National Center for Tumor Diseases, Heidelberg, to assess efficacy and toxicity in academic practice, especially focusing on older patients.

**Methods**

**Patients**

Requirements for inclusion were (1) histologically proven diagnosis of ductal pancreatic adenocarcinoma, (2) irresectable (metastasized or locally advanced) disease and (3) palliative first-line treatment with FOLFIRINOX at the NCT Heidelberg, Germany between January 2010 and June 2014. The observation period for each patient started with initiation of first-line treatment (i.e. first systemic chemotherapy after primary diagnosis of metastatic or inoperable disease or, in resected patients, after diagnosis of recurrence). The follow-up period for this analysis ended on July, 15th 2015. Survival data were available for all patients. The patients were identified with permission of two own institutional databases (the NCT clinical cancer registry, a prospectively maintained database and the registry of the pharmacy department of the University hospital Heidelberg, respectively).

**Treatment**

Full dose FOLFIRINOX consisted of oxaliplatin 85 mg/m², irinotecan 180 mg/m², leucovorin 400 mg/m², fluorouracil 400 mg/m² bolus and 2400 mg/m² over 46 h, q2w, as originally described [13]. Dose modifications were at the discretion of the treating physician.

**Assessment**

Clinical data were documented via an electronic medical record system. Information included Eastern Cooperative Oncology Group performance status (ECOG PS) [20], presence and site of metastases at diagnosis, date of previous surgery and adjuvant chemotherapy, start and stop date of FOLFIRINOX treatment, type and severity of toxicities and consecutive dose reductions, response to first-line therapy, date of progression, and date of death. Toxic effects were registered according to the National Cancer Institute’s common terminology criteria for adverse events (CTCAE). Tumor response was routinely evaluated according to the response evaluation criteria in solid tumors (RECIST, [21]).

**Statistical analysis**

Man Whitney U-Test and Fisher’s exact test were used for comparing independent samples of quantitative and binary data, respectively. Progression-free survival (PFS) was defined as time from start of palliative first-line treatment to documented tumor progression or death. Overall survival (OS) was defined as the time from start of palliative first-line treatment to death. Time-to event data were analyzed using standard methods, including Kaplan-Meier product-limit estimates. All analyses of prognostic factors were of an exploratory nature. Statistical analysis was performed using the SPSS statistical software, Version 22.

**Results**

**Patients’ demographics**

We identified 88 patients meeting the inclusion criteria. Median duration of observation was 10.4 months. The median age at diagnosis of advanced disease was 56 years (range 32–78), 15 patients (17%) were 65 years or older, and 8 patients (9%) were ≥70 years. 80 patients (91%) had died at the time of analysis. 50 patients (57%) had pancreatic head tumors, and 79 patients (90%) had metastatic disease. 22 patients (25%) had undergone prior tumor resection, and 13 (15%) had initially received adjuvant chemotherapy. 85 patients (97%) started therapy with an ECOG of 0 or 1. The main characteristics concerning both tumor disease and patient demographics did not differ significantly between younger (<65 years) and older (≥65 years) patients. The patient characteristics are summarized in Table 1.
FOLFIRINOX and toxicities

Median duration of first-line therapy with FOLFIRINOX was 150 days (range 14–787). Thirty-eight patients (43%) received therapy per protocol without any modifications during the course of treatment. Forty-six patients (52%) developed side effects that were classified as CTCAE grade 3 or higher: Hematologic side effects were found in 11 patients (13%), and 8 (9%) developed severe peripheral neuropathy. Six patients (7%) suffered from severe diarrhea, fatigue or cholangitis, respectively. Seven patients (8%) stopped therapy due to toxicity. There was no therapy-related death. Modifications of the FOLFIRINOX protocol were necessary in 50 patients. Median time to the first reduction was 74 days (range 0–287) after initiation of therapy. 12 patients (13.6%) had dosage modifications of only oxaliplatin of which 7 totally stopped and 5 continued therapy with 80% dosage. In 7 patients (8.0%), solely irinotecan, and in 5 patients (5.7%) the 5-fluorouracil bolus was dropped. 12 patients (13.6%) had a fixed reduction of all 3 cytotoxic drugs of 75–80% of the per-protocol dosage. 12 patients (13.6%) had dose reduction of varying degrees of two (4 patients) or three components (8 patients).

A summary of CTCAE Grade 3 and 4 toxicities is given in Table 2.

### Table 1 Patient characteristics

| Patient characteristics          | all   | <65 years | ≥ 65 years |
|---------------------------------|-------|-----------|------------|
| Number of Patients              | 88    | 73        | 15         |
| Median age (range), years       | 56 (32–78) | n (%) |
| Gender                          |       |           |            |
| Female                          | 31 (35.2) | 29 (39.7) | 2 (13.3)   |
| Male                            | 57 (64.8) | 44 (60.3) | 13 (86.7)  |
| ECOG PS                         |       |           |            |
| 0                               | 49 (55.7) | 43 (58.9) | 6 (40.0)   |
| 1                               | 36 (40.9) | 27 (37.0) | 9 (60.0)   |
| 2                               | 3 (3.4) | 3 (4.1)   | 0          |
| Metastatic disease              | 79 (89.8) | 64 (87.7) | 15 (100.0) |
| Locally advanced tumor          | 9 (10.2) | 9 (12.3)  | 0          |
| Primary palliative treatment    | 66 (75.0) | 55 (75.3) | 11 (73.3)  |
| Previous resection              | 22 (25.0) | 18 (24.7) | 4 (26.7)   |
| Prior (neo-) adjuvant CTX       | 13 (14.8) | 11 (15.1) | 2 (13.3)   |
| Site of Tumor                   |       |           |            |
| Pancreatic head                 | 50 (56.8) | 42 (57.5) | 8 (53.3)   |
| Pancreatic corpus               | 22 (25.0) | 20 (27.4) | 2 (13.3)   |
| Pancreatic tail                 | 16 (18.2) | 11 (15.1) | 5 (33.3)   |

### Table 2 Grade 3 or 4 toxicity according to the CTCAE (version 4)

| All, n (%) | <65 years | ≥ 65 years |
|------------|-----------|------------|
| Any grade ≥ 3 toxicity | 46 (52.3) | 41 (56.2) | 5 (33.3) |
| Hematological toxicity ≥ 3 | | | |
| Neutropenia | 2 (2.3) | 2 (2.7) | 0 |
| Febrile neutropenia | 1 (1.1) | 1 (1.4) | 0 |
| Thrombocytopenia/Anemia | 3 (3.4) | 3 (4.1) | 0 |
| Fatigue | 6 (6.8) | 4 (5.5) | 2 (13.3) |
| Nausea/Vomiting | 3 (3.4) | 1 (1.4) | 2 (13.3) |
| Diarrhea | 6 (6.8) | 5 (6.8) | 1 (6.7) |
| Cholangitis | 6 (6.8) | 5 (6.8) | 1 (6.7) |
| Thrombosis/Pulmonary embolism | 18 (20.5) | 17 (23.3) | 1 (6.7) |
| Treatment modifications due to toxicity | 50 (56.8) | 43 (58.9) | 7 (46.7) |
| Permanent treatment stop due to toxicity | 7 (8.0) | 4 (5.5) | 3 (20.0) |

### Progression and survival

Median PFS of our cohort was 6.4 months [95% CI 5.7;7.2]. It differed significantly between the ECOG groups: it was 6.9 months [95% CI 6.2;7.6] for patients with an ECOG PS 0, 5.4 months [95% CI 3.8;6.9] for ECOG PS 1 and 2.3 months [95% CI 1.0;3.6] for ECOG PS 2 (overall comparison $p = 0.019$) (Fig. 1). Patients needing dose reductions had a longer median PFS than those in the per-protocol group (7.4 months [95% CI 5.6;9.2] vs. 3.8 months [95% CI 0.9;6.8]; $p = 0.003$), however duration of therapy was significantly longer in this group: 180 days vs. 59 days ($p < 0.001$). Patients with therapy discontinuation due to toxicity had a significantly shorter PFS (2.5 months [95% CI 1.3;3.8] vs. 6.7 months [95% CI 6.0;7.4]; $p = 0.01$). There were no apparent PFS associations for metastasized compared to locally advanced tumors or for different tumor localizations.

Median OS in our patients was 10.2 months [95% CI 7.1;13.3], and also differed significantly between the ECOG groups with 11.8 months [95% CI 11.0;12.6] for patients with an ECOG PS 0, 7.9 months [95% CI 6.4;9.3] for ECOG PS 1 and 3.6 months [95% CI 2.4;4.8] for ECOG PS 2 (overall comparison $p = 0.003$) (Fig. 2). While dose modifications did not significantly influence OS ($p = 0.078$), patients with permanent therapy discontinuation due to toxicity lived significantly shorter (2.8 months [95% CI 2.3;3.3] vs. 11.5 months [95% CI 9.6;13.4]; $p < 0.001$). OS did not significantly differ between the groups of patients with metastasized compared to locally advanced tumors or for different tumor localizations.

### Comparison of different age groups

When we compared older patients (≥ 65 years) and younger patients, we did not find significant differences
in frequency of therapy interruptions, dosage modifications, or appearance of any toxicity CTCAE grade 3 or higher (Table 2). An age ≥65 years was not associated with significantly different PFS or OS. Median OS of patients ≥65 years was 7.9 months [95% CI 5.8;10.0] compared to 11.2 months [95%CI 8.9;13.6] for patients aged younger than 65 years, but this difference was not significant (p = 0.83).

**Discussion**

In the U.S., the median age at diagnosis of pancreatic cancer is 71 years (data for 2006–2010, seer.cancer.gov).
Two-thirds of patients are 65 years and older, and 41% are even 75 years or older. However, the FOLFIRINOX trial excluded patients older than 75 years (median age 61), and the vast majority of patients was even younger than 66 years (71%, 244 out of 342). Similarly, other clinical trials establishing the standard treatments for advanced pancreatic cancer had median ages between 62 and 64 years [12, 22, 23]. Although the MPACT trial introducing nab-paclitaxel + gemcitabine did not have an age limit, median age was also 63 years (range 27–88), with 42% of patients older than 65 years and 10% of patients older than 75 years [24].

In our heterogeneous academic outpatient collective, the survival times for first-line FOLFIRINOX treatment were in good accordance with the PRODIGE 4 trial collective and other retrospective analyses [17, 18]. 57% of our patients needed dose reductions, confirming the regimen’s substantial toxicity profile. Several authors have recommended using modified FOLFIRINOX regimens with reduced doses of chemotherapy to decrease the frequency of side effects. In our cohort, survival times for patients with dose reductions were not inferior to those receiving full-dose FOLFIRINOX, supporting the thesis that dose reductions might be possible without reducing efficacy [25]. The superior PFS of our patients with protocol adjustments is probably associated with the fact that dose reductions occurred more frequently in patients with a longer treatment period, reflecting the cumulative toxicity with prolonged chemotherapy. It might be a reasonable approach to start with full-dose FOLFIRINOX but to carefully monitor side effects and quickly adapt the doses if necessary. In patients that are deemed borderline fit for FOLFIRINOX, it might be wise to immediately start with a reduced dose to avoid toxicity-induced treatment discontinuation since this seems to be associated with a worse outcome. In terms of toxicities, no data for the different age groups were reported by the PRODIGE 4 trial authors. We did not find evidence that the subgroup of patients ≥65 years that was initially deemed fit enough for FOLFIRINOX treatment had an increased incidence of toxicities. In the PRODIGE 4 trial, the subgroup analysis showed no hint for a worse survival for patients between 65 and 74 years [13] and also in our analysis, the difference in OS for the age groups did not reach statistical significance. However, the small sample size of our old patients should be noted.

For gemcitabine-based palliative regimes, we have previously found that older patients with advanced pancreatic cancer with an ECOG PS of 0 or 1 do not have an inferior outcome or more toxicities than younger patients [26]. These findings are consistent with studies in other solid malignancies [27–29]. Thus, for advanced pancreatic cancer, the feasibility and efficacy of modern palliative chemotherapy regimens seems to be independent of chronological age. Our analysis highlights the prognostic impact of the initial ECOG PS, which allows a rapid evaluation of the patients’ resources with respect to tumor-specific treatment. In the pivotal PRODIGE 4 trial, only patients with an ECOG PS of 0 or 1 were included, and the MPACT trial included less than 10% of patients with an Karnofsky-score of less than 80%. Contrasting clinical trials with very strict inclusion criteria, “real-life” analyses include patients with more comorbidities and/or a reduced general condition. However, differences in the rated ECOG score between different physicians as well as different medical disciplines have been observed [30]. There is no doubt that older patients will have on average a worse ECOG PS and more comorbidities than younger patients, but the decision to withhold FOLFIRINOX from old patients based only on chronological age would not be reasonable and reflects a form of “ageism”. Whether a more intensive comprehensive geriatric assessment will translate into a superior rating regarding the tolerability of oncological treatment remains unknown. Some authors suggest that gemcitabine + nab-paclitaxel might be the preferred option in older patients given the lower incidence of several adverse events such as diarrhea in comparison to FOLFIRINOX. However, although independent phase III trials should only be directly compared very cautiously, the median overall survival rates clearly favor the FOLFIRINOX protocol (median OS 11.1 months for FOLFIRINOX vs. 8.7 months for gemcitabine/nab-paclitaxel) and this active combination should therefore be considered as a valuable treatment option for old patients in good PS.

The main limitation of our study is the small number of older patients and the retrospective, non-randomized nature of the analysis. It seems unlikely that a new randomized study on FOLFIRINOX in older patients will formally prove the benefit compared to gemcitabine monotherapy or gemcitabine/nab-paclitaxel in this patient group, but our study could serve as an encouragement to offer FOLFIRINOX also to older patients with good performance status. Finally, larger retrospective analyses, e.g. from cancer registers, might put our conclusions on a more solid fundament.

**Conclusion**

Our single-center experience confirms the FOLFIRINOX protocol being associated with a high rate of substantial side effects requiring dose reductions in more than half of the patients. We find some evidence, that dose reductions are possible without reducing clinical efficacy. Additionally, FOLFIRINOX seems to be a safe and efficient regimen for selected old patients with a good ECOG PS. It should not be withheld from patients solely based on the chronological age, avoiding any form of “ageism”.

Abbreviations
CTCAE: Common terminology criteria for adverse events; ECOG PS: Eastern Cooperative Oncology Group performance status; NCT: National Center for Tumor Diseases; OS: Overall survival; PFS: Progression-free survival; RECIST: Response evaluation criteria in solid tumors

Acknowledgements
Not applicable

Availability of data and materials
The clinical datasets supporting the conclusions of this article are available via the corresponding author.

Author contributions
AKB participated in study concepts and design, data acquisition, data analysis and interpretation, manuscript preparation and editing. GMH participated in quality control of data and algorithms, data analysis and interpretation, statistical analysis and manuscript preparation. AB and ME participated in data acquisition and manuscript preparation. DJ and CS participated in data analysis and interpretation and manuscript preparation and review. All authors read and approved the final manuscript.

Ethics approval and informed consent
The study was approved by the local Ethics Committee (Ethics Committee University of Heidelberg; S-267/2013, 24.09.2013). According to local ethics policy for retrospective analysis of own anonymized clinical data, informed consent was not obtained.

Consent for publication
Not applicable

Competing interests
The authors state that there are no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Im Neuenheimer Feld 460, 69120 Heidelberg, Germany. 2Pharmacy Department, Heidelberg University Hospital, Heidelberg, Germany. 3NCT Clinical Cancer Registry, German Cancer Research Center, Heidelberg, Germany.

Received: 21 March 2016 Accepted: 27 November 2017

Published online: 06 December 2017

References
1. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer. 1997;80(7):1273–83.
2. Yancik R. Population aging and cancer: a cross-national concern. Cancer J. 2005;11(6):437–41.
3. Weir HK, Thompson TD, Soman A, Moller B, Leadbetter S. The past, present, and future of cancer incidence in the United States: 1975 through 2020. Cancer. 2015;121(1):1827–37. doi: 10.1002/cncr.29258.
4. Smith BD, Smith GL, Hurria A, Hontobayani GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Natl Cancer Inst 2013;105(6):537–45. doi: 10.1093/jnci/djt079.
5. Kumar A, Soares HP, Balducci L, Djulbegovic B, National Cancer Institute. Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. J Clin Oncol. 2007;25(10):1272–6. doi: 10.1200/JCO.2006.02.8983.
6. Pallis AG, Fortpoid C, Wedding U, Van Nes MC, Penninckx B, Ring A, Lacombe D, Monfardini S, Scalliet P, Wildiers H. EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer. 2010; 46(9):1502–10. doi: 10.1016/j.ejca.2010.02.022.
7. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. doi: 10.3322/caac.21166.
8. Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. Cancer. 1995;76(9):1671–7.
9. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605–17. doi: 10.1056/NEJMra0910157.
10. Vincent A, Herman J, Schick R, Ruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378(9791):1670–2. doi: 10.1016/S0140-6736(11)63207-0.
11. NCT Clinical Cancer Registry, German Cancer Research Center, Heidelberg, Germany.
12. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raou JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennoua A, Bachet JB, Kermis-Akou F, Verge-Perge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Dureux M, Groupe Tumeurs Digestives de U, Intergroup P. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25. doi: 10.1056/NEJMoa1101923.
13. Coit DG, El-Rayes BF. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas. 2013;42(8):1311–7. doi: 10.1097/MPA.0b013e31827d3f6e.
14. Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, Wuthrich E, Williams TM, Reardon J, Ellison EC, Bloomston M, Bekaii-Saab T. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 2015;22(8):1513–9. doi: 10.1245/s10434-014-4225-1.
15. Ko AH. FOLFIRINOX: a small step or a great leap forward? J Clin Oncol. 2011;29(28):3727–9. doi: 10.1200/JCO.2011.37.3464.
16. Peddi PF, Lubner S, McWilliams R, Tan BR, Picus J, Sorscher SM, Suresh R, Lockhart AC, Wang J, Menias C, Gao F, Linehan D, Wang-Gillam A. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP. 2012;13(5):497–501. doi: 10.1097/JOPA.0b013e318255530c.
17. Gunturu KS, Yao X, Cong X, Thumar JR, Hochster HS, Stein LM, Lacy J. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol. 2013;30(1):361. doi: 10.1007/s12032-012-0361-2.
18. Mahaseth H, Brutzer E, Kauh J, Hawk N, Kim S, Chen Z, Kooby DA, Marthel SK, Landry J, El-Rayes BF. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas. 2013;42(8):1311–5. doi: 10.1097/MPA.0b013e31827e0a06.
19. Goldstein DJ, El-Marghini RH, Hamel P, Heinemann V, Kunzmann V, Sastre J, Scheithauer W, Siena S, Tabernero J, Teixeira L, Tortora G, Van Laethem JL, Young R, Penenberg DN, Lu B, Romano A, Von Hoff DD (2015) nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst 107 (2). doi:10.1093/jnci/dju413.
20. Oken MM, Creech RH, Torney DC, Horton J, Davis TE, McFadden ET, Carbop PP, Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 1982;5(6):649–55.
21. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dacey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2): 228–47. doi: 10.1016/j.ejca.2008.10.026.
22. Moore MJ, Goldstein D, Hamer J, Figar A, Hecht JR, Gallinger S, Au HH, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Pasynski M, Parulek W, National Cancer Institute of Canada Clinical Trials G (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical trials group. J Clin Oncol 25 (15):1960–1966. doi: 10.1200/JCO.2006.07.9525.
23. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crippen L, Adab F, Thompson J, Leonard P, Ostrowski J, Estalk M, Scheithauer W, Herrmann R, Neoptolemos JP, Phase III randomized comparison of gemcitabine versus gemcitabine plus capcitabine in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical trials group. J Clin Oncol 25 (15):1960–1966. doi: 10.1200/JCO.2006.07.9525.
24. von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seya T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Remi M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703. doi: 10.1056/NEJMoa1304369.
25. James ES, Cong X, Yao X, Hahn C, Kakey K, Li J, Kortmansky JS, Fischbach NA, Cha C, Salem RR, Stein S, Hochster HS, Lacy J. Final analysis of a phase II study of Yale-modified FOLFIRINOX (mFOLFIRINOX) in metastatic pancreatic cancer (mPC). J Clin Oncol (Meeting Abstracts). 2015;33(3_suppl):395.

26. Berger AK, Abel U, Komander C, Harig S, Jager D, Springfeld C. Chemotherapy for advanced pancreatic adenocarcinoma in elderly patients (≥70 years of age): a retrospective cohort study at the National Center for tumor diseases Heidelberg. Pancreatology. 2014;14(3):211–5. doi: 10.1016/j.pan.2014.03.004.

27. Hutson TE, Bukowski RM, Rini BI, Gore ME, Larkin JMG, Figlin RA, Barrios CH, Escudier B, Lin X, Fly KD, Martelli B, Matczak E, Motzer RJ. A pooled analysis of the efficacy and safety of sunitinib in elderly patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol (Meeting Abstracts). 2011;29(15):4604.

28. Folprecht G, Seymour MT, Saltz L, Douillard JY, Hecker H, Stephens RJ, Maughan TS, Van Cutsem E, Rougier P, Mitry E, Schubert U, Kohne CH. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol. 2008;26(9):1443–51. doi: 10.1200/JCO.2007.14.0509.

29. Berger AK, Zschaebitz S, Komander C, Jager D, Haag GM. Palliative chemotherapy for gastroesophageal cancer in old and very old patients: a retrospective cohort study at the National Center for tumor diseases, Heidelberg. World J Gastroenterol. 2015;21(16):4911–8. doi: 10.3748/wjg.v21.i16.4911.

30. Kim YJ, Hui D, Zhang Y, Park JC, Chisholm G, Williams J, Bruera E. Differences in performance status assessment among palliative care specialists, nurses, and medical oncologists. J Pain Symptom Manag. 2015;49(6):1050–1058 e1052. doi: 10.1016/j.jpainsymman.2014.10.015.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit